CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit
about
The Granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticityRetrograde labeling, transduction, and genetic targeting allow cellular analysis of corticospinal motor neurons: implications in health and diseaseStructural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migrationGranulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis.Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patientsGene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF.Analytical sequence to study G-CSF effect on the transcriptome of isolated spinal motoneurons from SOD1 G93A mice, an animal model for amyotrophic lateral sclerosis.Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trialNoninvasive tracking of gene transcript and neuroprotection after gene therapy.Healthy and diseased corticospinal motor neurons are selectively transduced upon direct AAV2-2 injection into the motor cortex.Intraspinal stem cell transplantation for amyotrophic lateral sclerosisTargeting the full length of the motor end plate regions in the mouse forelimb increases the uptake of fluoro-gold into corresponding spinal cord motor neuronsIncreased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis.Antioxidant gene therapy against neuronal cell death.Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis.Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.Gene therapy strategies for the treatment of spinal cord injury.Gene delivery in tissue engineering and regenerative medicine.Current developments in gene therapy for amyotrophic lateral sclerosis.Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice.Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.Safety of granulocyte colony-stimulating factor (G-CSF) administration for postrehabilitated motor complete spinal cord injury patients: an open-label, phase I study.Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis.
P2860
Q26798071-3C29A06B-D1CE-4BE8-999D-6095A9F3A860Q26823894-54C55039-167F-4F48-8E8D-8AEC70FC6560Q27678476-5E0DAC1F-C4B1-43D0-815D-B6CC344585D8Q33770796-782FBCDF-F97B-4795-B574-B560B43C5F98Q35137333-4024ABF0-5FF0-4C05-97B5-B5410BEC3093Q35291214-CB9D8DBD-E7D0-41D8-BA84-7AA7938F134EQ35555633-62A0B811-3EC9-4510-AB39-7838E18B0455Q35814080-75C67E4F-C5A3-4AF9-8D19-9B74A7017233Q36428437-23657285-63D8-468C-AF20-9053D449A08AQ36445653-A6B942AE-127C-40AB-96EC-BC5D0480A2AAQ36649800-2EE6914A-C09D-4D07-B967-F85120C1E5B0Q36679757-C76A4205-D6D1-4D8D-8011-97DB2ACD2A72Q36854770-E470B17A-A18A-43EB-A07E-03A5EA03A6CAQ36981069-093502D7-7849-4942-AAA6-404597C7E649Q37647941-1FD04E20-F647-4FC4-B9FF-B55928029F73Q37903420-84BEF2DB-6C03-4C71-B2DE-7AA4C52C6F52Q37957674-FF619592-97E8-44C3-BE70-82B611B4A6E5Q38226668-DEF0BC96-8E0A-49B7-A570-E7781FDE226BQ38306886-782AB2F2-0DDA-4C7C-B1EA-687A6B2213F9Q38470242-E42CAFCF-B45C-4817-B8BB-F7366A947234Q39331076-B00A5295-E619-4C64-A21E-A65109952574Q39639495-27D15566-AFD3-466B-9A9A-ED9C71ECA58DQ40236265-86011D1F-CDD0-40EC-A01A-584DFF7B8CDDQ47152662-518FB2E5-F8E7-4754-84B8-3BDE3EC58CB0Q49452570-6EDEA95A-6782-41AB-BEBE-43FB6D2E33B2
P2860
CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@ast
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@en
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@nl
type
label
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@ast
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@en
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@nl
prefLabel
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@ast
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@en
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@nl
P2093
P2860
P356
P1433
P1476
CNS-targeted viral delivery of ...... tion of the neuromuscular unit
@en
P2093
Alexandre Henriques
Claudia Pitzer
Luc Dupuis
Matthias Klugmann
Tanjew Dittgen
P2860
P304
P356
10.1038/MT.2010.271
P577
2010-12-07T00:00:00Z